Search results with tag "Genentech"
TNKase (Tenecteplase) DESCRIPTION - Genentech
www.gene.cominfusion of Activase® (Alteplase).1 Eligibility criteria included onset of chest pain within 6 hours of randomization and ST-segment elevation or left bundle branch block on electrocardiogram (ECG). Patients were to be excluded from the trial if they received GP IIb/IIIa inhibitors within the previous 12 …
ACTEMRA Medication Guide - Genentech
www.gene.comand the Southwest) where there is an increased chance for getting certain kinds of fungal infections (histoplasmosis, coccidiomycosis, or blastomycosis). These infections may happen or become more severe if you use ACTEMRA. Ask your healthcare provider, if you do not know if you have lived in an area where these infections are common.
OCREVUS Medication Guide - Genentech
www.gene.cominfections, and herpes infections. Infections are a common side effect, which can be serious.Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, or a cough that does not go away. Signs of herpes infection include: cold sores genital sores pain
and consider a change in treatment - Genentech
www.gene.comfactor VIII (FVIII) inhibitor titers. Intrinsic pathway clotting-based laboratory tests should not be used. (5.4, 7.2) ADVERSE REACTIONS Most common advers e reactions (incidence ≥ 10%) are injection site reactions, headache, and arthralgia. (6.1)
CELLCEPT Prescribing Information - Genentech
www.gene.comshould avoid inhalation or contact of the skin or mucous membranes with the powder contained in CELLCEPT capsules and oral suspension. If such contact occurs, they must wash the area of contact thoroughly with soap and water. In case of ocular contact, rinse eyes with plain water.
ESBRIET Prescribing Information - Genentech
www.gene.com· Recommended dosage: 801 mg three times daily (2403 mg/day). (2) ... gastro-esophageal reflux disease, and abdominal pain were more frequently reported by ... Subjects ages ranged from 40 to 80 years (mean age of 67 years). Most patients were male (74%) and Caucasian (95%). The mean duration of exposure to
XOFLUZA Prescribing Information - Genentech
www.gene.comHypersensitivitysuch as anaphylaxis, angioedema,urticaria,and erythema multiforme: Initiate appropriate treatment if an allergic-like reaction occurs or is suspected. (5.1) Risk of bacterial infection:Serious bacterial infections may begin with influenza-like symptoms or may coexist with, or occur as,a complication of influenza.
XOLAIR Prescribing Information - Genentech
www.gene.comclinical studies with adult patients included the following: headache, injection site reaction, arthralgia, upper abdominal pain, and dizziness. (6.1) Chronic Spontaneous Urticaria: The most common adverse reactions ( 2% of patients) included …
OCREVUS Prescribing Information - Genentech
www.gene.comOCREVUS® (ocrelizumab) injection, for intravenous use Initial U.S. Approval: 2017-----RECENT MAJOR CHANGES-----Dosage and Administration (2.1, 2.3) 12/2020 Warnings and Precautions(5.2, 5.3) 11/2020 ... and possibly other pre-medication to reduce the risk of infusion reactions prior to each infusion]was34to 40%,withthe highest incidence with ...
RITUXAN Prescribing Information - Genentech
www.gene.comcyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens. 1.2 Chronic Lymphocytic Leukemia (CLL) RITUXAN, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL.
HIGHLIGHTS OF PRESCRIBING INFORMATION ... - Genentech
www.gene.comEmbryo-Fetal Toxicity: Exposure to Herceptin during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia and neonatal death.Advise patients of these risks and the need for effective contraception. (5.3, 8.1, 8.3)-----INDICATIONS AND USAGE-----
Valcyte Master USPI - Genentech
www.gene.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VALCYTE ® safely and effectively. See full prescribing information …
Reference ID: 4212951 - Genentech
www.gene.com3 Table 2. Recommended Dose Modifications for COTELLIC for Adverse Reactions Severity of Adverse Reactiona Dose Modification for COTELLIC New Primary Malignancies (cutaneous and non-cutaneous)
Genentech Patient Foundation Patient Consent Form
www.gene.comdetermine Genentech Patient Foundation eligibility. Education and patient support services: Optional programs offered by Genentech to help you start and stay on your medicine. Services may vary based on your medical condition and could include co-pay assistance, clinical support, marketing communication and general disease information.